

NIH HIV/AIDS CLINICAL TRIALS NETWORKS
Financial Disclosure and Conflict of Interest
Standard Operating Procedure

Owner	Office of HIV/AIDS Network Coordination (HANC)
-------	--

		
Adopted By		
		

Version History	Version 14	Effective 4 June 2025
-----------------	------------	-----------------------

NIH HIV/AIDS CLINICAL TRIALS NETWORKS
Financial Disclosure and Conflict of Interest Guidelines
Standard Operating Procedure

Table of Contents

1.0 General Principles	1
2.0 Definitions	1
3.0 Responsibilities	2
3.1 Network Members Required to Report Under This Policy	2
3.2 Financial Disclosure Coordinator (FDC)	3
3.3 Review Committee	3
3.4 Network Operations Center	3
3.5 PHS	4
APPENDIX Guidelines for Completing Statement of Financial, Equity, and Intellectual Property Interests	5

HIV/AIDS CLINICAL TRIALS NETWORKS

Financial Disclosure and Conflict of Interest Guidelines

Standard Operating Procedure

1.0 General Principles

[Title 42 CFR Part 50 Subpart F](#), “Promoting Objectivity in Research” - this subpart promotes objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, and reporting of research funded under U.S. Public Health Service (PHS) grants or cooperative agreements will be free from bias resulting from Investigator financial conflicts of interest. This requires the networks to establish and manage a system that ensures the research is not biased by any conflicting financial interest.

In order to satisfy this requirement for the PHS, the following guidelines have been developed and are intended to identify significant financial interests of researchers in the NIH HIV/AIDS Clinical Trials Networks and avoid conflicts of interest, or the appearance of such conflicts, in activities of the networks.

Network members and affiliated investigators play many professional roles and it is expected that network members have non-network professional activities. Such interactions might be viewed as ones that engender conflicts of interest and/or influence the decisions of members as they relate to the networks. This document outlines the networks' approach to collecting disclosures of significant financial interest from investigators in leadership roles. Submission of a financial disclosure statement to the network(s) does not release members from their own institutions' conflict of interest submission requirements nor the requirement for collection of financial disclosures by your site for FDA-regulated studies.¹

Disclosure of significant financial interests by network members will allow for perceived conflicts of interest to be addressed by the appropriate network review committee. Please contact your network(s) for more information on the review and resolution of perceived conflicts of interest.

2.0 Definitions

See <https://www.ecfr.gov/current/title-42/section-50.603> for the current definitions.

The most recent HHS rule on “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors” can be found at:

<https://www.federalregister.gov/documents/2011/08/25/2011-21633/responsibility-of-applicants-for-promoting-objectivity-in-research-for-which-public-health-service>.

¹ NOTE: This SOP does not address or satisfy FDA Financial Disclosure by Clinical Investigators Requirements identified in [21 CFR 312.53](#) and [21 CFR 812.43](#) which state that the IND/IDE sponsor shall obtain sufficient accurate financial information that will allow an applicant of a marketing application to submit complete and accurate certification or disclosure statements as required under [21 CFR 54](#). Members may be required to submit additional conflict of interest reports at the request of an IND holder. For more information, please view the DAIDS/RSC Protocol Registration Office [website](#).

3.0 Responsibilities

3.1 Network Members Required to Report Under This Policy

All network members who are required to report under this policy must complete an online “Statement of Financial, Equity, and Intellectual Property Interests” at least annually, or when joining a protocol team or committee. The Financial Disclosure Coordinator (FDC) (via the cross-network online reporting system) will inform network members required to report of the need to submit a new or revised “Statement of Financial, Equity, and Intellectual Property Interests” annually as determined by the networks. If there is a significant change in the member’s interests in the following year, it is incumbent upon the member to report said change to his/her network at the time of the change. Each completed statement should cover the previous 12 months and present day circumstances. Members new to the network and who are required to report must submit the statement within 60 days of joining the network. Members are obliged to report their financial, equity, and intellectual property interests until one year after the completion of the study as defined by DAIDS (i.e.; primary analysis is complete, primary manuscript is accepted, and all participants are off study). Failure to provide the statement by the stated deadline will result in suspension of member participation in committee and protocol team activities until a statement is received.

In the event that a network clinical trials site will discontinue participation in network-sponsored studies, the financial disclosure policy will continue to apply for a 12-month period subsequent to the final protocol visit completed at the site, or until the protocol database at the network statistical and data management center is officially locked, whichever is sooner. In the event of a clinical trial staff member being involved in a manuscript, the network financial disclosure policy will continue for this member until the manuscript is completed or the staff member no longer collaborates on it.

It is a network expectation that members required to disclose under this policy are taking the appropriate actions to ensure that they are in compliance with the financial disclosure requirements of their home institutions. Network members are also required to inform their home institutions of any conflict of interest identified by a network review committee.

If a conflict is identified by the network’s review committee, the individual must prepare or agree to an appropriate conflict management plan describing one or more actions to manage, reduce, or eliminate such conflicts of interest. This management plan should include an answer to the question of whether the individual and Network believes that the significant financial interest poses a conflict of interest, i.e., will a decision made by a group benefit the member voting on a matter and thus potentially influence his/her vote? The management plan may include, but is not limited to, the following:

- ☐ Monitoring of research activities by independent reviewers;
- ☐ Modification of the research plan;
- ☐ Disqualification from participation in all or a portion of the study(ies);
- ☐ Divestiture of significant financial interests that create conflicts;
- ☐ Severance of relationships that create conflicts;
- ☐ Recusal from voting on questions or matters involving products of the entity in question or its direct competitors (i.e., those entities having a similar scientific mission – development of HIV vaccine, topical microbicide HIV prevention product, HIV treatment products, etc.)

In any case in which it is determined that network-affiliated research whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by a network member with a conflicting interest that was not disclosed or managed as required, the member must disclose the conflicting interest in each public presentation of the results of

the research.

If an individual does not agree with the decision of the chair(s) of the relevant committees regarding a significant financial interest posing a conflict of interest which, in turn, requires a conflict management plan, the individual may appeal the decision. To do so, the network member should refer to his/her respective network(s) policies and procedures guide.

3.2 Financial Disclosure Coordinator (FDC)

An FDC will collect the statements, maintain a database of records, and follow network policies on managing significant financial interests.

3.3 Review Committee

Open disclosure is the primary means of managing conflicts of interest. If the relevant committee(s) are aware of the network members' disclosure, degrees of involvement, and status on teams, actions and/or statements of those members can be evaluated based on knowledge of the disclosure. A conflict of interest exists when the relevant chair(s) reasonably determines that a significant financial interest could directly and significantly affect the design, conduct, or reporting of PHS-funded research [see 42 CFR 50.603, "Financial Conflict of Interest"]. If the relevant chair(s) determines a conflict exists, the chair(s) will request that the network member submit in writing a proposed conflict management plan that may be approved or modified by the relevant chair(s).

The review committee members will consider the submitted conflict management plan and report their findings to the relevant Network Operations Center.

3.4 Network Operations Center

An FDC shall be appointed by the network operations center to maintain a secure record of all Statements of Financial, Equity, and Intellectual Property Interests submitted to the operations center.

Database records of network members disclosing significant financial interests in a relevant entity will be maintained to assist the relevant committee chair(s) and protocol chairs to determine whether potential conflicts of interest exist. If a conflict is identified, the network operations center will document and assist in the administration of the resulting conflict management plan.

eRA Commons Module Reporting: The network operations center and/or grantee institution will inform the relevant funding agency chief grants management officer or chief contracting officer, as appropriate, of the existence of any financial conflict of interest before spending any PHS funds awarded under a new award. Conflicts identified during the award period will be reported to the PHS within 60 days of identifying them. *The networks and/or grantee institutions will report all conflicts of interest through the [online eRA Commons FCOI Module](#). These reports will indicate whether the conflict of interest has been managed, reduced, or eliminated.*

The network operations center will maintain records of all actions taken by the network with respect to each conflict of interest for at least three years from the date of the final expenditure report of the grant and make information available to the Department of Health and Human Services as necessary regarding all conflicts of interests identified by the network and how those conflicts of interest have been managed, reduced, or eliminated.

The network operations center and/or grantee institution is required to ensure public accessibility, via a publicly accessible website or written response to any requestor within five business days of a request,

of information concerning any significant financial interest disclosed to the institution that meets the following three criteria:

- ❑ The significant financial interest was disclosed and is still held by the investigator;
- ❑ The institution determines that the significant financial interest is related to the network research; and
- ❑ The institution determines that the significant financial interest is a financial conflict of interest.

The information to be made public will include, at a minimum: the member's name; the title and role with respect to the research project; the name of the entity in which the significant financial interest is held; the nature of the significant financial interest; and the approximate dollar value of the significant financial interest; or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Information concerning the significant financial interests of an individual subject to paragraph will remain available, for responses to written requests or for posting via the network's and/or grantee institution's publicly accessible website for at least three years from the date that the information was most recently updated.

The network operations center will maintain copies of the conflict management plans approved by the relevant committees.

3.5 PHS

When PHS staff has concerns that a conflict or perceived conflict of interest may exist, the concerns and relevant information will be forwarded to the relevant committee(s) for determination and appropriate action. PHS representatives at NIH Division of AIDS (DAIDS) will consult with the relevant committee(s) about any general issue or specific problem that may arise during the course of any DAIDS-sponsored trial.

The Director of DAIDS or his/her designee may review these guidelines and make appropriate recommendations.

An audit of the Financial Disclosure and Conflict of Interest Program of the network (including guidelines, education, and implementation) may be undertaken by DAIDS as part of the performance evaluation of the group.

APPENDIX

Guidelines for Completing Statement of Financial, Equity, and Intellectual Property Interests

On the *NIH HIV/AIDS Clinical Trial Networks Statement of Financial, Equity, and Intellectual Property Interests* form, please use the following categories when listing the activities for which you or a family member receive financial compensation, have equity interest, or have intellectual property interest.

- ☐ Direct salary support or other direct benefits from industry-sponsored research
- ☐ Consultant fee, direct and indirect (including lecture/seminar fees)
- ☐ Teaching fees
- ☐ Service grant, contract, or membership on scientific/clinical advisory board
- ☐ Equipment
- ☐ Gift
- ☐ Honoraria
- ☐ Stock owned by you or a family member
- ☐ Stock option owned by you or a family member
- ☐ Mutual funds owned by you or a family member, only if you have/the family member has direct control over the investment decisions.
- ☐ Copyrights
- ☐ Royalties
- ☐ Travel ***Not applicable to ACTG.**
- ☐ Equity Interest
- ☐ Intellectual property rights with relevant entities with a significant financial interest (patents, pending patents, copyrights, licensures, and royalties) or potential earnings from any patent held by any other party.

If there is a significant change in the member's interests, it is incumbent upon the member to report said change to his/her network at the time of the change. Each completed statement should cover the previous 12 months and present day circumstances.

Please confirm need to declare individual interests before submitting the Statement of Financial, Equity, and Intellectual Property Interests.

The most recent HHS rule on "Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors" can be found at: <https://www.federalregister.gov/documents/2011/08/25/2011-21633/responsibility-of-applicants-for-promoting-objectivity-in-research-for-which-public-health-service>.

Additional NIH guidance can be found at: <http://grants.nih.gov/grants/policy/coi/index.htm>.

For substantive questions concerning the HHS Rule, email: FCOICompliance@mail.nih.gov.

For questions about network-specific policies and procedures (including conflict management processes), please refer to your network(s)' operation center or member website.